Looking for volunteers
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
NCT05419089 · Icahn School of Medicine at Mount Sinai · Updated 22 July 2026
- What is being tested
- Robotic surgery
- For
- HPV-positive Oropharyngeal Squamous Cell Carcinoma
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years and older. About 83 people. The full rules are on the registry page.
- Where
- United States (2 sites)
- When
- Starts or started 12 July 2022, ends June 2029. Registered 15 June 2022.
- Results
- None posted yet.
In the researchers' words
The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with transoral robotic surgery (TORS) alone can result in cancer control and survival comparable to those previously reported with standard therapy. The protocol includes patients with only with low or intermediate pathologic risk factors following surgery with detectable pre-surgery cfHPVDNA and undetectable post-surgery cfHPVDNA. The hope is that with this approach, the long-term complications from chemotherapy and radiation can be reduced.
Sites
- Valley - Mount Sinai Comprehensive Cancer CareParamus, New Jersey, United States
- Mount Sinai Health SystemNew York, New York, United States